Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Martin Pharmaceuticals General Information
Recent findings from the DREAM study (Phase 2a open-label trial) evaluated the safety and efficacy of docarpamine in patients with refractory ascites. The trial enrolled 16 patients with refractory ascites requiring regular large-volume paracentesis, who received either a low dose (750 mg TID) or a high dose (1500 mg TID) of docarpamine for up to 90 days. The company has announced positive results from this study.
Contact Information
Primary Industry
Biotech
Corporate Office
New York, New York
United States
United States
Drug Pipeline
docarpamine
Phase 2Key Partnerships
Mitsubishi Tanabe Pharma Corporation (MTPC)
Martin Pharmaceuticals Funding
No funding data available
To view Martin Pharmaceuticals's complete valuation and funding history, request access »